Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Indaptus Therapeutics, Inc.

Ticker
INDP
Sector
Industry
Report date
November 13, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Indaptus Therapeutics' clinical trial progress, capital raises, management changes, and patent approvals, alongside its position as a leading biotech stock gainer in recent months.

Recent developments:
  • Indaptus Therapeutics has been recognized among leading biotech stock gainers in recent market activity, reflecting investor interest [N1].
  • The company entered a $6 million securities deal and appointed David Lazar as Co-CEO and Chairman in late 2025 [N4].
  • Indaptus raised $5.7 million through convertible promissory notes and warrants in mid-2025 [N6].
  • The company secured $2.3 million in funding through convertible promissory notes and warrants in June 2025 [N7].
  • Indaptus launched a Phase 1 study to evaluate Decoy20 in combination with Tislelizumab in early 2025 [N8].
  • Enrollment in the Phase 1 trial of Decoy20 exceeded 20 patients, achieving a key clinical milestone in early 2025 [N5].
  • The company secured new patent approvals for its Decoy platform in China, Japan, and Israel in early 2025 [N5].
  • Management changes in 2026 include resignations of Co-CEO David Lazar and Chief Scientific Officer Michael Newman, indicating a transition period [S2].
  • The company has discontinued enrollment in its Combination Study and currently has no active clinical development programs [S2].
Overview

Indaptus Therapeutics, Inc. operates as a clinical-stage biotechnology company developing a patented systemically-administered anti-cancer and anti-viral immunotherapy platform. Its product candidates are in preclinical or early clinical stages, with no approved or commercialized products. The company has discontinued enrollment in its Combination Study and currently has no active clinical development programs. Research and development expenses constitute a significant portion of operating costs, primarily related to third-party CROs and CMOs. Indaptus has secured patent approvals for its Decoy platform in China, Japan, and Israel and has conducted Phase 1 clinical trials evaluating Decoy20 in combination with Tislelizumab, including expansion of trials to Canada. The company is evaluating strategic alternatives including potential transactions and collaborations to advance its business. Recent management changes and capital raises through convertible promissory notes and securities deals have occurred. Financially, as of September 30, 2026, the company held approximately $26.6 million in cash and equivalents, reported a net loss of about $1.05 million for the quarter, and maintained strong liquidity ratios. Risks include significant dilution potential from convertible preferred stock, ongoing operating losses, and uncertainties related to clinical development and financing.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Indaptus Therapeutics, Inc. is a clinical-stage biotech company focused on developing a novel immunotherapy platform with all candidates in early development stages. The company has discontinued enrollment in its combination clinical study and currently has no active clinical programs. It has raised capital through securities deals and convertible notes, with cash and equivalents of approximately $26.6 million as of September 30, 2026. Recent management changes and strategic evaluations introduce operational uncertainties. Risks include significant dilution from convertible preferred stock, ongoing losses, and uncertainties in clinical development and financing [S1][S2][N1][N4][N5][N6][N7][N8].

Scenarios for INDP

Bull case model:

Indaptus Therapeutics has developed a novel patented immunotherapy platform with international patent protections, which could provide a foundation for future therapeutic products. The company has demonstrated progress through Phase 1 clinical trials and expansion of its Decoy20 program, indicating potential clinical validation. Recent capital raises and securities deals have provided liquidity to support ongoing operations and strategic evaluations. The company's focus on both anti-cancer and anti-viral indications may offer multiple avenues for development and partnerships. If strategic alternatives lead to successful collaborations or acquisitions, the company could leverage its technology and clinical data to advance its pipeline.

Bear case model:

Indaptus Therapeutics faces significant challenges as a clinical-stage biotech with no approved products and discontinued enrollment in its combination clinical study. The company has no active clinical development programs currently and is evaluating strategic alternatives amid operational uncertainties. Ongoing net losses and cash burn raise concerns about long-term financial sustainability without additional financing. Significant dilution risk exists due to convertible preferred stock that could concentrate control and reduce existing stockholder influence. The company also faces risks from macroeconomic conditions, regulatory hurdles, and uncertainties in clinical development timelines and costs. Management changes and potential disruptions during transition periods add to execution risks.

Moat:

Indaptus Therapeutics' moat is primarily based on its proprietary and patented Decoy platform technology targeting anti-cancer and anti-viral immunotherapy applications. The company has secured patent approvals in multiple international jurisdictions, including China, Japan, and Israel, which provide intellectual property protection for its platform. However, as a clinical-stage biotech company with no approved products or commercial revenues, its competitive advantage depends heavily on successful clinical development, regulatory approvals, and the ability to secure strategic partnerships or transactions. The company's early-stage status and ongoing financial losses limit its current moat strength, with significant execution and financing risks ahead.

Risks overview
Risks summary
The most significant risks for Indaptus Therapeutics include substantial dilution and control concentration from convertible preferred stock, uncertainty in clinical development progress with no active programs, and financial sustainability concerns amid ongoing losses and cash burn.
Risks details:

• Dilution and Control Risk: Conversion of preferred stock could result in issuance of approximately 111 million common shares, representing about 96.4% of fully diluted shares, significantly diluting existing stockholders and concentrating control with a single investor.
• Clinical Development Uncertainty: Discontinuation of enrollment in the Combination Study and absence of active clinical programs create uncertainty about future product development and regulatory approvals.
• Financial Sustainability: The company has incurred significant operating losses and cash outflows, with substantial doubt about its ability to continue as a going concern without additional financing or strategic transactions.
• Management and Operational Transition: Recent resignations and changes in executive management may disrupt operations and strategic initiatives during the transition period.
• Market and Liquidity Risks: Reverse stock splits and authorized share increases may impact stock price and liquidity, potentially affecting investor interest and trading volumes.
• Macroeconomic and Regulatory Risks: Economic conditions such as inflation and interest rates may affect capital access; regulatory approvals and clinical trial progress are subject to significant uncertainties and delays.

FINAL FORECAST FOR INDP

Final take one line
Indaptus Therapeutics is a clinical-stage biotech with a patented immunotherapy platform facing operational transitions, financial challenges, and strategic uncertainty amid ongoing clinical development and capital raises.
Final take 12 to 24 month view

Business trends: The company is navigating clinical trial discontinuations, management changes, and strategic evaluations while maintaining patent protections and raising capital.
Execution milestones: Key clinical milestones include Phase 1 trial enrollment achievements and patent approvals; capital raises and management appointments have occurred.
Key risks: Significant dilution and control concentration, clinical development uncertainties, financial sustainability concerns, and operational disruptions during management transitions.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy platform.
  • All product candidates are in preclinical or early clinical development stages; none have received marketing approval or are commercialized as of the latest filings.
  • The company has discontinued enrollment in its Combination Study and currently has no active clinical development programs.
  • Research and development expenses are a significant portion of operating expenses, primarily fees to CROs and CMOs, and employee compensation related to R&D activities.
  • The company expenses R&D costs as incurred and accrues expenses based on estimates of services performed by third parties.
  • Indaptus has secured patent approvals in China, Japan, and Israel for its Decoy platform targeting HIV and HBV treatment.
  • The company launched a Phase 1 study to evaluate Decoy20 in combination with Tislelizumab and expanded the Decoy20 clinical trial to Canada.
  • Recent management changes include appointment and resignation of key executives, including Co-CEO and Chairman David Lazar, and Chief Scientific Officer.
  • The company entered a $6 million securities deal and raised additional funds through convertible promissory notes and warrants in multiple rounds.
  • As of September 30, 2026, Indaptus reported cash and cash equivalents of approximately $26.6 million and a net loss of about $1.05 million for the quarter.
  • Liquidity ratios as of 2026-09-30 include a current ratio of 2.34 and a cash ratio of 36.01, indicating a strong short-term liquidity position.
  • The company has significant risks related to its limited operating history, ongoing losses, and uncertainty about future financing and strategic direction.
  • Stockholders face dilution risks due to convertible preferred stock that could represent approximately 96.4% of common stock upon conversion, concentrating control with a single investor.
  • The company has authorization to increase common stock shares and to effect reverse stock splits, which may impact stock price and liquidity.
  • Indaptus is evaluating strategic alternatives including potential transactions, collaborations, or acquisitions to advance its business and development programs.
  • The company has disclosed risks related to macroeconomic conditions, regulatory approvals, and uncertainties in clinical development timelines and costs.
  • Recent news highlights include the company leading biotech stock gainers, clinical milestones in Decoy20 trials, and patent approvals in multiple countries.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-17 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-09-15 | www.nasdaq.com | Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers | https://www.nasdaq.com/articles/biotech-stocks-gain-ground-pds-biotech-clene-indaptus-lead-movers
  • N2 | 2026-06-18 | www.nasdaq.com | Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-qure-rallies-amt-130-update-lnai-track-fth-eyes-q4-data-eltx-watch
  • N3 | 2026-05-26 | www.nasdaq.com | Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-aktx-rallies-govx-ebola-concerns-slgl-awaits-catalysts-cmmb-watch
  • N4 | 2025-12-29 | www.nasdaq.com | Indaptus Therapeutics Enters $6 Million Securities Deal, Appoints David Lazar Co-CEO And Chairman | https://www.nasdaq.com/articles/indaptus-therapeutics-enters-6-million-securities-deal-appoints-david-lazar-co-ceo-and
  • N5 | 2025-08-13 | www.nasdaq.com | Indaptus Posts Narrower Loss in Q2 | https://www.nasdaq.com/articles/indaptus-posts-narrower-loss-q2
  • N6 | 2025-07-01 | www.nasdaq.com | Indaptus Therapeutics Raises $5.7 Million Through Convertible Promissory Notes and Warrants | https://www.nasdaq.com/articles/indaptus-therapeutics-raises-57-million-through-convertible-promissory-notes-and-warrants
  • N7 | 2025-06-13 | www.nasdaq.com | Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round | https://www.nasdaq.com/articles/indaptus-therapeutics-inc-secures-23-million-through-convertible-promissory-notes-and
  • N8 | 2025-03-18 | www.nasdaq.com | Indaptus Therapeutics Launches Phase 1 Study To Evaluate Decoy20 Combination With Tislelizumab | https://www.nasdaq.com/articles/indaptus-therapeutics-launches-phase-1-study-evaluate-decoy20-combination-tislelizumab
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine